BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16123505)

  • 1. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes.
    Gillespie EL; White CM; Kardas M; Lindberg M; Coleman CI
    Diabetes Care; 2005 Sep; 28(9):2261-6. PubMed ID: 16123505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL; Baker WL; White CM
    Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis.
    Al-Mallah M; Khawaja O; Sinno M; Alzohaili O; Samra AB
    Cardiol J; 2010; 17(5):448-56. PubMed ID: 20865674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of angiotensin receptor blockers in the prevention of type 2 diabetes and cardiovascular events: a meta-analysis of randomized trials.
    Song HF; Wang S; Li HW
    Chin Med J (Engl); 2012 May; 125(10):1804-10. PubMed ID: 22800904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.
    Al Khalaf MM; Thalib L; Doi SA
    Am J Cardiovasc Drugs; 2009; 9(1):29-43. PubMed ID: 19178130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
    Abuissa H; Jones PG; Marso SP; O'Keefe JH
    J Am Coll Cardiol; 2005 Sep; 46(5):821-6. PubMed ID: 16139131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
    McCall KL; Craddock D; Edwards K
    Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
    Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
    Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
    Andraws R; Brown DL
    Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
    Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
    J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
    Shih CJ; Chu H; Ou SM; Chen YT
    Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.
    Maione A; Navaneethan SD; Graziano G; Mitchell R; Johnson D; Mann JF; Gao P; Craig JC; Tognoni G; Perkovic V; Nicolucci A; De Cosmo S; Sasso A; Lamacchia O; Cignarelli M; Manfreda VM; Gentile G; Strippoli GF
    Nephrol Dial Transplant; 2011 Sep; 26(9):2827-47. PubMed ID: 21372254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.
    Jandeleit-Dahm KA; Tikellis C; Reid CM; Johnston CI; Cooper ME
    J Hypertens; 2005 Mar; 23(3):463-73. PubMed ID: 15716683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
    Liu Y; Ma X; Zheng J; Jia J; Yan T
    BMC Nephrol; 2017 Jun; 18(1):206. PubMed ID: 28666408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis.
    Lv X; Zhang Y; Niu Y; Song Q; Zhao Q
    Medicine (Baltimore); 2018 Apr; 97(15):e0256. PubMed ID: 29642146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.